Filing Analysis
Grace Therapeutics, Inc. filed an 8-K to announce its financial results for the three months ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Three months ended June 30, 2026
- The company issued a press release (Exhibit 99.1) containing the financial results.
Grace Therapeutics, Inc. completed a private placement offering of 4,761,904 shares of common stock at $2.10 per share, raising approximately $10 million in gross proceeds. The transaction includes a registration rights agreement to allow for the future resale of these shares.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of over 4.7 million new shares.
- Registration rights agreement creates potential future selling pressure as investors can liquidate their holdings once the registration statement becomes effective.
📋 Key Facts
- Offered and sold 4,761,904 shares of Common Stock at $2.10 per share.
- Gross proceeds from the offering are approximately $10 million (before fees).
- The offering closed on August 6, 2026.
- Craig-Hallum Capital Group LLC acted as the placement agent.
- A Registration Rights Agreement was executed to register the shares for resale.
- Includes a standstills/restriction period preventing certain equity transactions or reverse splits for at least 90 days from the closing date.
Grace Therapeutics announced receipt of FDA meeting minutes following a Type A Meeting regarding its GTx-104 New Drug Application (NDA). The company has updated its corporate presentation to outline the resubmission path after receiving a Complete Response Letter in April 2026.
🚩 Red Flags
- The company is operating under a Complete Response Letter (CRL), indicating the FDA previously declined approval for GTx-104.
- High dependency on the outcome of the GTx-104 resubmission, which is critical for a micro-cap biotech.
📋 Key Facts
- Received FDA meeting minutes from a Type A Meeting held on July 28, 2026.
- The meeting addressed the Complete Response Letter (CRL) issued by the FDA on April 23, 2026.
- Subject of discussion is the GTx-104 new drug application (NDA).
- Company updated its corporate presentation to reflect the path toward NDA resubmission.
Grace Therapeutics, Inc. filed an 8-K to disclose the update of its corporate presentation. The updated presentation, dated June 17, 2026, was attached as Exhibit 99.1.
📋 Key Facts
- The filing date is June 18, 2026.
- The company updated its corporate presentation as of June 17, 2026.
- The presentation is filed under Item 8.01 (Other Events).
Grace Therapeutics, Inc. filed an 8-K to announce the issuance of a press release regarding its financial results for the fiscal year ended March 31, 2026.
📋 Key Facts
- The filing date is June 18, 2026.
- The company reported financial results for the fiscal year ending March 31, 2026.
- The results were disseminated via a press release (Exhibit 99.1).
Grace Therapeutics announced the departure of Carrie D’Andrea as Vice President of Clinical Operations effective June 5, 2026. To ensure continuity, the company entered into a twelve-month consulting agreement with Ms. D’Andrea.
🚩 Red Flags
- Departure of a key executive overseeing Clinical Operations in a therapeutics company can signal internal instability or delays in clinical trial execution.
📋 Key Facts
- Carrie D’Andrea ceased serving as VP of Clinical Operations effective June 5, 2026.
- A twelve-month Consulting Agreement was signed on June 5, 2026, with a fee of $250 per hour.
- Stock option vesting will continue as long as Ms. D’Andrea provides services under the Consulting Agreement.
- Ms. D’Andrea will have 90 days post-consulting termination to exercise vested options.
- Severance benefits are contingent upon a release of claims and adherence to non-competition/non-solicitation covenants.
Grace Therapeutics, Inc. filed an 8-K to announce an update to its corporate presentation on April 27, 2026. The updated presentation was included as an exhibit to the filing for public disclosure.
📋 Key Facts
- The filing was made on April 27, 2026, under Item 8.01 (Other Events).
- An updated corporate presentation dated April 27, 2026, was attached as Exhibit 99.1.
- The report was signed by Chief Executive Officer Prashant Kohli.
Grace Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for GTx-104. The drug was intended for the treatment of patients with aneurysmal subarachnoid hemorrhage, and the CRL indicates the application will not be approved in its current form.
🚩 Red Flags
- Regulatory rejection (CRL) of a lead drug candidate's NDA.
- Significant uncertainty regarding the timeline and cost for potential re-submission.
- Potential requirement for additional clinical trials or data to address FDA concerns.
📋 Key Facts
- The FDA issued the Complete Response Letter on April 23, 2026.
- The NDA was for GTx-104, a candidate for aneurysmal subarachnoid hemorrhage.
- A CRL means the FDA has completed its review but cannot approve the application as submitted.
- The company issued a press release (Exhibit 99.1) regarding the regulatory decision.
Grace Therapeutics, Inc. filed an 8-K to announce its financial results for the three months ended December 31, 2025. The filing serves as a formal notification that a press release containing these results was issued on February 12, 2026.
📋 Key Facts
- Reporting period: Three months ended December 31, 2025.
- Filing date: February 12, 2026.
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Grace Therapeutics, Inc. has entered into several amendments to the employment and severance agreements for its top executive team, including the CEO, CFO, VP of Program Management, VP of Clinical Operations, and CMO.
🚩 Red Flags
- Significant increase in potential cash outflows and equity acceleration triggered by a 'Change in Control' scenario.
- The simultaneous amendment of nearly the entire C-suite/senior leadership team often precedes significant corporate restructuring or M&A activity.
📋 Key Facts
- Amendments were made on January 10, 2026, to existing letter agreements for five key executives: Prashant Kohli (CEO), Robert J. DelAversano (PFO/VP Finance), Amresh Kumar (VP Program Management), Carrie D’Andrea (VP Clinical Operations), and R. Loch Macdonald (CMO).
- The amendments specifically supersede and replace certain severance terms in the original agreements.
- In a termination without Cause (absent Change in Control), the CEO is entitled to 12 months of base salary and COBRA, while other executives receive 6 months.
- In the event of a Change in Control, severance for the CEO increases to 18 months of base salary plus target bonus, with full vesting of equity awards.
Grace Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2025, and provided an updated corporate presentation including recent cash position data.
📋 Key Facts
- Announced financial results for the three months ended September 30, 2025 (Item 2.02).
- Updated corporate presentation released on November 13, 2025 (Item 8.01).
- The updated presentation includes the company's cash position as of October 31, 2025.
- Signed by CEO Prashant Kohli.
Grace Therapeutics, Inc. announced it has secured approximately $4.0 million in additional funding through the exercise of common warrants from a September 2023 private placement. This follows the expiration of over 1.19 million remaining warrants triggered by an FDA milestone regarding their GTx-104 drug candidate.
🚩 Red Flags
- Reliance on warrant exercises for liquidity suggests a need for immediate cash infusion.
- The expiration of over 1.1 million warrants indicates significant dilution or potential capital structure shifts depending on the exercise price (though not explicitly stated).
📋 Key Facts
- Secured ~$4.0 million in funding via exercise of common warrants.
- Warrants originated from a private placement closed in September 2023.
- 1,190,927 common warrants expired after the 60th day following FDA acceptance of the GTx-104 New Drug Application (NDA) for review.
- GTx-104 is an injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage.
Grace Therapeutics announced that the U.S. Patent and Trademark Office issued a new patent (No. 12,414,943) for the parenteral administration of nimodipine. This patent extends the intellectual property protection for their lead candidate, GTx-104, through 2043.
📋 Key Facts
- Patent No. 12,414,943 issued for 'Nimodipine Parenteral Administration'.
- The patent covers the dosing regimen for I.V. administration used in the Phase 3 STRIVE-ON safety trial.
- Patent protection for GTx-104 is extended to the year 2043.
- GTx-104 is a clinical-stage injectable formulation of nimodipine targeting aneurysmal subarachnoid hemorrhage.
Grace Therapeutics, Inc. held its Annual Meeting of Stockholders on September 12, 2025. The meeting resulted in the successful election of five directors and the approval of executive compensation and the appointment of KPMG LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on September 12, 2025.
- Quorum reached with 7,926,945 shares represented (57.32% of outstanding shares).
- Five directors elected: Vimal Kavuru, A. Brian Davis, Prashant Kohli, S. George Kottayil, and Edward Neugeboren.
- Advisory vote to approve named executive officer compensation was approved.
- Stockholders ratified the appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending March 31, 2026.
Grace Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for GTx-104, a novel injectable formulation of nimodipine. The FDA has set a PDUFA target date of April 23, 2026, for the review of this application.
📋 Key Facts
- FDA accepted NDA for GTx-104 for formal review on August 22, 2025.
- GTx-104 is an injectable formulation of nimodipine for aneurysmal subarachnoid hemorrhage.
- PDUFA target date set for April 23, 2026.
Grace Therapeutics, Inc. filed an 8-K to announce its financial results for the three months ended June 30, 2025. The filing serves as a formal notice of the earnings release issued on August 12, 2025.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Three months ended June 30, 2025
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Grace Therapeutics, Inc. announced the submission of a New Drug Application (NDA) to the FDA for its clinical-stage drug candidate GTx-104. The product is an injectable formulation of nimodipine intended for patients with aneurysmal subarachnoid hemorrhage.
📋 Key Facts
- Filed on June 25, 2025
- Submission of New Drug Application (NDA) to the FDA for GTx-104
- GTx-104 is a novel, injectable formulation of nimodipine
- Target indication: aneurysmal subarachnoid hemorrhage patients via IV infusion
Grace Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal year ended March 31, 2025.
📋 Key Facts
- Company announced financial results for the fiscal year ended March 31, 2025.
- The announcement was made via a press release dated June 23, 2025.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
Grace Therapeutics, Inc. announced alignment with the FDA regarding its planned New Drug Application (NDA) submission for GTx-104, an injectable formulation of nimodipine intended for aneurysmal subarachnoid hemorrhage patients.
📋 Key Facts
- Company is planning a New Drug Application (NDA) submission for GTx-104.
- GTx-104 is a clinical-stage, novel, injectable formulation of nimodipine.
- The drug is intended for IV infusion to treat aneurysmal subarachnoid hemorrhage.
- FDA alignment has been reached regarding the planned submission.
Grace Therapeutics, Inc. filed an 8-K to update its corporate presentation, specifically addressing the company's cash position and projected financial runway. This type of disclosure is often used by micro-cap biotech firms to provide transparency regarding liquidity constraints or upcoming capital requirements.
🚩 Red Flags
- Implicit liquidity risk: Updating 'runway guidance' often signals a need for imminent capital raising or concerns over current cash burn rates.
📋 Key Facts
- Filed on March 3, 2025
- Updated corporate presentation includes updated cash position details
- Updated corporate presentation includes revised runway guidance
- The filing is under Item 8.01 (Other Events)
Grace Therapeutics, Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal quarter ended December 31, 2024.
📋 Key Facts
- Report date: February 13, 2025
- Reporting period: Fiscal quarter ended December 31, 2024
- Company name change noted: Formerly known as Acasti Pharma Inc.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
Grace Therapeutics, Inc. announced a private placement offering of 3,252,132 shares of common stock and pre-funded warrants at $3.395 per share, aiming to raise approximately $13.8 million in net proceeds. The filing also includes positive Phase 3 clinical trial results for the STRIVE-ON safety trial.
🚩 Red Flags
- Significant potential dilution: The offering includes common warrants to purchase an aggregate of 4,418,292 shares of Common Stock (or Pre-Funded Warrant Shares).
- Restrictive covenants: A 'Restricted Period' prevents the company from issuing new equity or effecting a reverse stock split for at least 90 days post-closing or until registration is effective.
📋 Key Facts
- Offering size: 3,252,132 shares of common stock and up to 1,166,160 pre-funded warrants.
- Pricing: $3.395 per share/pre-funded warrant; Common Warrants issued at an aggregate price included in the offering.
- Expected net proceeds: Approximately $13.8 million after fees and expenses.
- TD Securities (USA) LLC acted as the placement agent.
- The company will register for resale of the Shares and Warrant Shares via a registration statement.
- Phase 3 STRIVE-ON safety trial met its primary endpoint, showing clinical benefit over nimodipine.
Grace Therapeutics, Inc. filed an 8-K to furnish its quarterly press release for the fiscal quarter ended September 30, 2024. This is a routine earnings announcement filing.
📋 Key Facts
- Reporting period: Fiscal quarter ended September 30, 2024.
- Filing date: November 13, 2024.
- The company recently underwent a name change from Acasti Pharma Inc. to Grace Therapeutics, Inc.
Grace Therapeutics, Inc. has amended its Certificate of Incorporation to change its corporate name from Acasti Pharma Inc. to Grace Therapeutics, Inc. The ticker symbol is also changing from 'ACST' to 'GRCE' on the Nasdaq Stock Market.
📋 Key Facts
- Corporate name changed from Acasti Pharma Inc. to Grace Therapeutics, Inc., effective October 28, 2024.
- Ticker symbol changed from 'ACST' to 'GRCE' on the Nasdaq Stock Market, effective October 28, 2024.
- The change was executed via a Certificate of Amendment filed with the Secretary of State of Delaware.
- Bylaws were amended to reflect the name change; no other changes were made to the Bylaws.
- CUSIP number (00439U104) remains unchanged.
Acasti Pharma Inc. announced a corporate name change to 'Grace Therapeutics, Inc.' and a ticker symbol change from 'ACST' to 'GRCE', effective October 28, 2024. The company also scheduled a virtual Key Opinion Leader Event for November 20, 2024.
📋 Key Facts
- Corporate name changing from Acasti Pharma Inc. to Grace Therapeutics, Inc.
- Effective date of name change: October 28, 2024
- Ticker symbol changing from ACST to GRCE on Nasdaq
- Scheduled Key Opinion Leader Event: November 20, 2024
Acasti Pharma Inc. completed a multi-step corporate reorganization, moving its jurisdiction of incorporation from Québec to British Columbia and finally to Delaware. The company also entered into indemnification agreements with executive officers and directors as part of the domestication process.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Shareholders approved continuance and domestication at the Annual and Special Meeting on September 30, 2024.
- Continuance from Québec to British Columbia was effective October 1, 2024.
- Domestication from British Columbia to Delaware was effective October 7, 2024.
- The company entered into indemnification agreements with all executive officers and directors on October 7, 2024.
- Common stock continues to trade on Nasdaq under the symbol 'ACST'.
Acasti Pharma Inc. held its Annual and Special Meeting of Shareholders on September 30, 2024, where shareholders approved several key corporate restructuring and governance matters.
📋 Key Facts
- Shareholders approved the Acasti Pharma Inc. 2024 Equity Incentive Plan.
- KPMG was appointed as the Company’s independent registered public accounting firm.
- Shareholders approved a two-step domestication process: first from Québec to British Columbia, and then from British Columbia to Delaware.
- The Meeting saw a quorum of 70.50% (7,149,326 shares) of the outstanding common shares.
- All five directors were re-elected by significant majorities.
Acasti Pharma Inc. announced the completion of patient enrollment for its pivotal Phase 3 STRIVE-ON safety trial on September 25, 2024.
📋 Key Facts
- The company has completed enrollment for the Phase 3 STRIVE-ON safety trial.
- Announcement made via press release dated September 25, 2024.
- The filing is an Item 8.01 (Other Events) disclosure.
Acasti Pharma Inc. announced a new employment agreement for its Chief Executive Officer, Prashant Kohli, effective August 12, 2024.
🚩 Red Flags
- Severance package includes 12 months of base salary in the event of termination without cause or following a change of control.
📋 Key Facts
- Prashant Kohli entered into an employment agreement as CEO on August 12, 2024.
- Annual base salary is set at $500,000.
- Discretionary bonus potential of up to 50% of the annual base salary.
- Agreement includes a 12-month base salary continuation if terminated by the Company without Cause (including after a change of control).
- The agreement contains standard confidentiality, non-competition, and non-solicitation obligations.
Acasti Pharma Inc. filed an 8-K to furnish its quarterly press release regarding financial results for the fiscal quarter ended June 30, 2024.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Financial results were announced via a press release dated August 9, 2024.
- The reporting period covers the fiscal quarter ended June 30, 2024.
Acasti Pharma Inc. announced that its pivotal Phase 3 STRIVE-ON safety trial has surpassed the 50% enrollment milestone as of June 27, 2024.
📋 Key Facts
- Phase 3 STRIVE-ON safety trial exceeded the 50% enrollment milestone on June 27, 2024.
- The announcement was made via a press release incorporated by reference as Exhibit 99.1.
Acasti Pharma Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal year ended March 31, 2024.
📋 Key Facts
- Report date: June 21, 2024
- Fiscal year end reported: March 31, 2024
- The filing is primarily to furnish Exhibit 99.1 (Press Release) regarding results of operations and financial condition.
Acasti Pharma Inc. filed an 8-K to provide an updated corporate presentation as part of a Regulation FD disclosure. This is a routine informational filing intended to update investors on the company's current business status and outlook.
📋 Key Facts
- The filing was made on April 1, 2024.
- The primary purpose is to furnish an updated corporate presentation (Exhibit 99.1).
- Information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 liability.
Acasti Pharma Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal quarter ended December 31, 2023.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Fiscal quarter ended December 31, 2023.
- Filing date: February 12, 2024.
Acasti Pharma Inc. announced a leadership change in its finance department, appointing Robert J. DelAversano as Principal Financial Officer and Principal Accounting Officer, effective January 5, 2024.
🚩 Red Flags
- Removal of an interim CFO suggests a transition from temporary to permanent financial leadership, which can sometimes indicate internal restructuring or stabilization efforts.
📋 Key Facts
- Robert J. DelAversano appointed as Principal Financial Officer (PFO) and Principal Accounting Officer (PAO), effective Jan 5, 2024.
- Brian Ford removed from the position of interim-Chief Financial Officer; he will remain as a financial consultant on an as-needed basis.
- Mr. DelAversano's compensation includes a $290,000 annual base salary and a target bonus opportunity of up to 30%.
- Awarded 42,000 stock options with an exercise price of $2.125 per share, vesting over 36 months in quarterly installments.
- Mr. DelAversano previously served as VP, Finance at Acasti since November 2023.